ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2014

Difficult to Treat Rheumatoid Arthritis: Prevalence of Different Objective Patterns, Predictive Characteristics, and Associated Factors in 1-Year Follow-Up

Einer Sanchez-Prado, ronald Perez, Laura Cuellar, jonatan mareco, Santiago Ruta, Sebastian Magri and Rodrigo Garcia Salinas, Hospital Italiano de La Plata, La Plata, Argentina

Meeting: ACR Convergence 2022

Keywords: Response Criteria, rheumatoid arthritis, risk factors, Therapy, alternative

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: RA – Treatment Poster IV

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Difficult-to-Treat Rheumatoid Arthritis (RA) (D2T), is a concept recently defined by EULAR, it refers to patients who do not achieve the therapeutic target, who have failed two biological or Jaki and present difficult management.

Objectives: To estimate the frequency of different objective patterns of D2T in a one-year follow-up. To analyze the RA features at basal and one year associated with D2T.

Methods: A prospective cohort study, where patients diagnosed with RA recruited from a comprehensive program was included. In the first visit (baseline) the following were performed: blood test, X-ray, ultrasound, and an interview where sociodemographic data, clinical data, and clinimetry; each evaluator was unaware of the data from the other studies performed. One year later they were evaluated in the same program with the same procedures and the treatment carried out by their rheumatologist during that period was recorded. Compliance with D2T criteria was established according to the failure of two biological or Jaki and the objective parameters and classification defined in figure 1. Statistical analysis: descriptive statistics, Chi2 test, Fisher’s exact test, Student’s T-test, and Mann Whitney were performed. Multivariate analysis of logistic regression of the significant variables at baseline and at one year for each objective definition of D2T.

Results: We included 120 patients with RA who completed the baseline visit and at one year, 77% were a female, mean age of 52 years (SD: 13), disease duration 30 months (IQR: 12-70), 49% had diagnosis less than 2 years, 84% seropositive. The frequency of D2T RA in each definition is shown in figure 1. In the univariate analysis, in general, seropositivity, high cholesterol, the presence of radiographic damage, the indication of biologicals, and smoking at baseline were associated with the development of RA D2T, and positive ultrasound at a year was the variable associated with D2T, and HAQ improvement was negative. Multivariate analysis for each objective definition of D2T with their respective independent associations is shown in figure 2.

Conclusion: The frequency of RA D2T in our cohort at one year of follow-up was between 8% and 48% depending on the objective definition used, it was independently associated with high activity at baseline, ACPA seropositivity, high cholesterol, smoking, erosions on Rx and indication of Jaki. And after a year with activity in ultrasound and in a negative way with the improvement of the HAQ.

Supporting image 1

Supporting image 2


Disclosures: E. Sanchez-Prado, None; r. Perez, None; L. Cuellar, None; j. mareco, None; S. Ruta, None; S. Magri, None; R. Garcia Salinas, Eli Lilly, Janssen, Novartis, GlaxoSmithKlein(GSK), Genentech, BMS, Merck, UCB, Pfizer.

To cite this abstract in AMA style:

Sanchez-Prado E, Perez r, Cuellar L, mareco j, Ruta S, Magri S, Garcia Salinas R. Difficult to Treat Rheumatoid Arthritis: Prevalence of Different Objective Patterns, Predictive Characteristics, and Associated Factors in 1-Year Follow-Up [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/difficult-to-treat-rheumatoid-arthritis-prevalence-of-different-objective-patterns-predictive-characteristics-and-associated-factors-in-1-year-follow-up/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/difficult-to-treat-rheumatoid-arthritis-prevalence-of-different-objective-patterns-predictive-characteristics-and-associated-factors-in-1-year-follow-up/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology